来源：新浪证券-红岸工作室 9月24日，君实生物涨0.22%，成交额6.21亿元。两融数据显示，当日君实生物获融资买入额6709.54万 元，融资偿还4696.78万元，融资净买入2012.75万元。截至9月24日，君实生物融资融券余额合计14.29 亿元。 融资方面，君实生物当日融资买入6709.54万元。当前融资余额14.23亿元，占流通市值的4.46%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，君实生物9月24日融券偿还2.09万股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量13.60万股，融券余额566.81万元，超过近一年50%分位水平，处于较高位。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0. ...

每经AI快讯，9月25日，港股君实生物(01877.HK)涨超6%，截至发稿，涨6.34%，报31.54港元，成交额 1.82亿港元。 ...

Core Viewpoint - Junshi Biosciences (01877) shares rose over 6%, currently up 6.34% at HKD 31.54, with a trading volume of HKD 182 million [1] Group 1: Upcoming Conference - The European Society for Medical Oncology (ESMO) annual meeting will be held in Berlin, Germany from October 17 to October 21, 2025 [1] - Junshi Biosciences will present over 20 studies on its innovative products, including anti-PD-1 monoclonal antibody Toripalimab, anti-BTLA monoclonal antibody Tifcemalimab, and selective PI3K-α inhibitor JS105 at the conference [1] Group 2: Research Highlights - The conference's latest breakthrough abstracts (Late-Breaking Abstracts, LBA) have been announced, with two studies on Toripalimab selected for oral presentations [1] - One of the studies on Toripalimab has been chosen for the prestigious Proffered Paper session, showcasing cutting-edge advancements in combination therapy [1]

Core Viewpoint - Junshi Biosciences (01877) shares rose over 6%, currently up 6.34% at HKD 31.54, with a trading volume of HKD 1.82 billion [1] Group 1: Upcoming Conference - The European Society for Medical Oncology (ESMO) annual meeting will take place from October 17 to October 21, 2025, in Berlin, Germany [1] - Junshi Biosciences will present over 20 studies on its innovative products, including anti-PD-1 monoclonal antibody Toripalimab, anti-BTLA monoclonal antibody Tifcemalimab, and selective PI3K-α inhibitor JS105 at the conference [1] Group 2: Research Highlights - The conference's latest breakthrough abstracts (Late-Breaking Abstracts, LBA) have been announced, with two studies on Toripalimab selected for oral presentations [1] - One of the studies has been honored with a spot in the prestigious Proffered Paper session, showcasing advancements in Toripalimab combination therapy [1]

资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 君实生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、创新 药、抗癌药物、抗癌治癌、猴痘概念等。 来源：新浪证券-红岸工作室 9月25日，君实生物盘中上涨2.18%，截至09:35，报42.58元/股，成交5648.08万元，换手率0.17%，总市 值437.16亿元。 资金流向方面，主力资金净流入31.36万元，特大单买入306.69万元，占比5.43%，卖出0.00元，占比 0.00%；大单买入1392.73万元，占比24.66%，卖出1668.05万元，占比29.53%。 君实生物今年以来股价涨55.80%，近5个交易日跌6.89%，近20日跌3.16%， ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biopharmaceutical developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2]. - Junshi's self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - Junshi's subsidiary, JunTuo Biotech, is developing vaccine-related products, including monkeypox and Zika vaccines, which are currently in preclinical development [3]. - The company has partnered with several institutions, including Peking University and the Chinese Academy of Sciences, to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi Biosciences reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, a 36.01% increase [8]. - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, with a decrease in average circulating shares per person by 5.56% [8]. Market Activity - On September 24, Junshi Biosciences' stock rose by 0.22%, with a trading volume of 621 million yuan and a turnover rate of 1.95%, bringing the total market capitalization to 42.782 billion yuan [1]. - The stock has seen a net outflow of 27.407 million yuan from major funds, indicating a lack of strong buying interest [4][5].

Core Viewpoint - The A-share market is experiencing a significant rebound, particularly in the Sci-Tech Innovation Board, with the ETF Huatai-PineBridge (589120) showing a notable increase of 1.59% as of 13:54 on September 24, and attracting over 20 million yuan in net subscriptions within three trading days [1][3]. Group 1: ETF Performance - The Huatai-PineBridge Sci-Tech Innovation Drug ETF (589120) has seen strong performance, with most of its constituent stocks rising, including Teva Biopharma up over 3%, and several others like Zai Lab and Eucure Biopharma rising over 2% [3]. - The top ten constituent stocks of the ETF include notable companies such as RYSE Pharmaceuticals (688235) with a weight of 9.92% and a rise of 1.93%, and Eucure Biopharma (688578) with a weight of 8.03% and a rise of 2.27% [4]. Group 2: Market Dynamics - The National Healthcare Security Administration is set to hold a communication meeting in Beijing to discuss negotiations and pricing with companies, marking a significant innovation in this year's healthcare directory adjustments [5]. - The current innovation drug market is driven by the trend of "local innovation - global monetization," which is seen as a key support for the industry's growth [6]. - Analysts from Xinda Securities believe that the trend of innovation in the drug sector is not over, with expectations for continued growth in innovative drugs, medical devices, and AI healthcare [7]. Group 3: Industry Outlook - Tianfeng Securities highlights that the Chinese innovative drug industry has achieved significant results and is now globally competitive, entering a phase of self-sustainability through commercialization [8]. - The industry is supported by favorable policies, a well-structured talent pool, and a collaborative approach between academia and industry, which enhances the efficiency of drug development [9]. - The future outlook suggests that increasing innovation will further unlock commercial value, with China becoming one of the most efficient countries in the drug development process [10].

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020, focusing on the research and commercialization of monoclonal antibodies and therapeutic proteins [7] - The company's main revenue sources include 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] - As of June 30, 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, a year-on-year increase of 36.01% [8] Group 2: Product Pipeline and Innovations - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - Junshi Biosciences is advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2] - The company is also collaborating with various research institutions to develop vaccines, including monkeypox and Zika vaccines, which are currently in preclinical development [3] Group 3: Market Performance and Investor Sentiment - On September 23, Junshi Biosciences' stock fell by 4.26%, with a trading volume of 755 million yuan and a market capitalization of 42.69 billion yuan [1] - The stock has seen a net outflow of 48.4 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5] - The average trading cost of the stock is 41.93 yuan, with the stock price approaching a resistance level of 42.00 yuan, suggesting potential volatility [6]

Group 1 - Junshi Bioscience's stock closed at 41.58 yuan, with a decline of 4.26%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share [1] - The highest stock price recorded on the first day of trading was 220.40 yuan [1] Group 2 - The total funds raised from the initial public offering amounted to 4.836 billion yuan, with a net amount of 4.497 billion yuan after deducting issuance costs, exceeding the original plan by 1.797 billion yuan [1] - The planned fundraising amount was 2.7 billion yuan, allocated for innovative drug research and development, industrialization projects, bank loan repayment, and working capital [1] - The issuance costs for the initial public offering were 339 million yuan, including 320 million yuan for sponsorship and underwriting fees [1] Group 3 - In 2022, Junshi Bioscience raised 3.7765 billion yuan by issuing 70 million A-shares at a price of 53.95 yuan per share [2] - After deducting issuance costs of approximately 31.7 million yuan, the actual net amount raised was about 3.7448 billion yuan [2] - The total amount raised from both public offerings is 8.612 billion yuan [2] Group 4 - From 2016 to 2024, the net profit attributable to shareholders showed consistent losses, with figures ranging from -135 million yuan to -2.388 billion yuan [3] - In the first half of 2025, the company reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, but still recorded a net loss of 413 million yuan [3] - The net cash flow from operating activities was -329 million yuan, an improvement from -865 million yuan in the same period last year [3]

Core Viewpoint - The company has announced the public disclosure and verification of the list of initial incentive recipients for its 2025 A-share stock option incentive plan, which was approved by the board and supervisory committee [2][9]. Disclosure and Verification Process - The company held meetings on September 2, 2025, to approve the stock option incentive plan and related proposals [2]. - The initial list of incentive recipients was publicly disclosed on the Shanghai Stock Exchange website on September 3, 2025, along with the plan draft and summary [2][3]. - A public notice period of 10 days was established from September 3 to September 13, 2025, during which employees could raise objections [3]. - No objections were received by the supervisory committee by the end of the public notice period [4]. Supervisory Committee's Verification - The supervisory committee verified the list of initial incentive recipients, including their qualifications and employment contracts [5]. - The committee confirmed that all listed individuals meet the qualifications as per the Company Law, management regulations, and company charter [6]. - The committee ensured that none of the recipients fell under disqualifying conditions outlined in the management regulations, such as being deemed inappropriate candidates by regulatory bodies within the last 12 months [7][8]. - The basic information of the incentive recipients was verified to be accurate, with no falsehoods or significant omissions [8].